Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Vivoryon Therapeutics NV banner

Vivoryon Therapeutics NV
AEX:VVY

Watchlist Manager
Vivoryon Therapeutics NV Logo
Vivoryon Therapeutics NV
AEX:VVY
Watchlist
Price: 1.37 EUR -0.72% Market Closed
Market Cap: €40.6m
Write Note Create Alert Ask AI

Vivoryon Therapeutics NV
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also
Income Statement

Vivoryon Therapeutics NV
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Vivoryon Therapeutics NV
AEX:VVY
Research & Development
-€14.1m
CAGR 3-Years
7%
CAGR 5-Years
-24%
CAGR 10-Years
-6%
BioNTech SE
NASDAQ:BNTX
Research & Development
-€2.3B
CAGR 3-Years
-35%
CAGR 5-Years
-63%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Research & Development
-€141.4m
CAGR 3-Years
44%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Research & Development
-€176m
CAGR 3-Years
-20%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Research & Development
-€56.9m
CAGR 3-Years
-4%
CAGR 5-Years
-2%
CAGR 10-Years
2%
Formycon AG
XETRA:FYB
Research & Development
-€15.5m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vivoryon Therapeutics NV
Glance View

Market Cap
40.6m EUR
Industry
Biotechnology

The company is headquartered in Halle, Sachsen-Anhalt and currently employs 16 full-time employees. The company went IPO on 2014-10-27.

VVY Intrinsic Value
Not Available
What is Intrinsic Value?

See Also

What is Vivoryon Therapeutics NV's Research & Development?
Research & Development
-14.1m EUR

Based on the financial report for Dec 31, 2024, Vivoryon Therapeutics NV's Research & Development amounts to -14.1m EUR.

What is Vivoryon Therapeutics NV's Research & Development growth rate?
Research & Development CAGR 10Y
-6%

Over the last year, the Research & Development growth was 20%. The average annual Research & Development growth rates for Vivoryon Therapeutics NV have been 7% over the past three years , -24% over the past five years , and -6% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 318,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.